About Moleculin Biotech, Inc. - Common Stock (MBRX)
Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of innovative therapies for the treatment of cancer. The company specializes in designing and manufacturing drug candidates that target aspects of cancer biology, with a commitment to addressing significant unmet needs in oncology. Leveraging its proprietary technologies, Moleculin Biotech is engaged in advancing a pipeline of drug candidates aimed at effectively treating various types of cancer by improving therapeutic efficacy and minimizing toxicity. Through rigorous research and clinical trials, the company seeks to bring new hope to patients battling challenging forms of cancer. Read More
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of their
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
